Developer docs
API playgroundTry for free, no card

Search company profiles

Sequoia Vaccines, Inc

Full company profile

uuid00yjobt

Namestring
Sequoia Vaccines, Inc
Legal namestring
Sequoia Vaccines, Inc.
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Sequoia Vaccines, Inc. is a privately held, clinical-stage pharmaceutical company advancing a three-program pipeline of vaccine and small-molecule therapeutics. The portfolio is anchored by SEQ-400, a FimH-based vaccine designed to prevent recurrent urinary tract infections as a non-antibiotic alternative, an area situated at the intersection of unmet medical need and the public-health priority around antimicrobial resistance. A second program, SEQ-1274, is a small-molecule platform targeting ovarian and uterine cancer, while a third undisclosed-structure small-molecule platform is directed at cystic fibrosis lung infections. The technology base spans FimH adhesin-based vaccinology and proprietary small-molecule chemistry across infectious disease and oncology indications.

The pipeline addresses three distinct patient populations: women with recurrent UTIs, patients with gynecologic malignancies, and individuals with cystic fibrosis experiencing chronic pulmonary infections. Each program targets a therapeutic area where existing standard of care is either antibiotic-dependent (contributing to AMR), sub-optimal in efficacy, or both. The disclosed leadership group has more than 100 years of combined experience and is supported by a scientific advisory board, although specific credentials are not enumerated in the available data.

As a clinical-stage entity with no disclosed approvals, partnerships, or commercial sales, Sequoia Vaccines' business model is pre-commercial. Value creation is expected to derive from advancing assets through clinical milestones, securing regulatory designations (e.g., FDA priority review, breakthrough, or orphan pathways, particularly under AMR-focused STEDI principles), and eventually out-licensing, partnering, or directly commercializing approved products. No pricing, manufacturing, or go-to-market mechanics are disclosed at this stage.

Short descriptiontext

Sequoia Vaccines, Inc. is a privately held, clinical-stage pharmaceutical company developing a three-program pipeline (SEQ-400 FimH vaccine for recurrent UTIs, SEQ-1274 small molecules for ovarian/uterine cancer, and a CF lung-infection small-molecule platform) for patients affected by antimicrobial-resistant infections and gynecologic cancers.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
vaccine development, antimicrobial resistance, oncology therapeutics, small-molecule drug platform, recurrent UTI prevention
Industry2 codes
PRIMARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Vaccine & Small-Molecule Therapeutics
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company developing a three-program pipeline: SEQ-400, a FimH-based vaccine for the prevention of recurrent urinary tract infections; the SEQ-1274 small-molecule drug platform for the treatment of ovarian, uterine, and other cancers; and a novel small-molecule drug platform for treating lung infections associated with cystic fibrosis. The portfolio combines vaccine and small-molecule approaches targeting antimicrobial resistance and gynecological cancers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company with a three-program product pipeline. The portfolio includes SEQ-400, a FimH vaccine for preventing recurrent UTIs; the SEQ-1274 small-molecule platform targeting ovarian and uterine cancers; and a novel small-molecule drug platform for treating lung infections in cystic fibrosis patients. These programs collectively address antimicrobial resistance and cancer.

Product and service3 records
1SEQ-400
CategoryVaccine (Anti-infective)
Description

SEQ-400 is a FimH vaccine candidate under clinical-stage development for the prevention of recurrent urinary tract infections. FimH is a bacterial adhesin protein found on the surface of uropathogenic E. coli, and the vaccine is intended to interrupt bacterial adhesion, reducing rUTI recurrence and antibiotic dependency.

2SEQ-1274 Drug Platform
CategorySmall-Molecule Oncology Therapeutics
Description

SEQ-1274 is a small-molecule oncology drug platform generating candidates for the treatment of ovarian, uterine, and other cancers. The platform is designed to deliver small-molecule therapeutics intended for gynecological and broader oncology indications.

3Novel Small Molecule Drug Platform for Cystic Fibrosis
CategorySmall-Molecule Anti-Infective (Respiratory)
Description

A drug platform composed of novel small-molecule lead compounds being optimized for the treatment of bacterial lung infections in cystic fibrosis patients, targeting chronic and biofilm-associated infections in the CF lung.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global vaccine and immuno-oncology company with mRNA and protein-based vaccine platforms addressing infectious disease and oncology. Comparable in modality (vaccines) and oncology adjacency to Sequoia's small-molecule and vaccine programs.

TypeBroad incumbent
Description

Global pharmaceutical incumbent with both vaccine and oncology franchises (Prevnar, oncology portfolio). Comparable as a benchmark for vaccine manufacturing, regulatory navigation, and oncology small-molecule development that Sequoia would need to compete against or partner with.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing novel small-molecule and biologic therapies, including anti-infectives. Comparable as a small clinical-stage peer with multi-program pipeline across infectious disease and oncology.

TypeEmerging player
Description

Clinical-stage small-molecule oncology company developing targeted therapies for cancer indications with high unmet need. Comparable in being a small private/clinical-stage biotech with a small-molecule platform addressing oncology indications similar to Sequoia's SEQ-1274 program.

TypeEmerging player
Description

Clinical-to-commercial vaccine biotech using protein-subunit and nanoparticle vaccine platforms. Comparable to Sequoia in relying on recombinant protein-subunit vaccine technology, though at a much later development stage and broader indication scope.

TypeBroad incumbent
Description

Established vaccine biotech with a broad mRNA and protein-subunit vaccine pipeline, including infectious disease programs. Comparable as a large-scale vaccine platform operator; Sequoia is a much smaller, narrowly focused peer in the vaccine technology space.

TypeEmerging player
Description

Clinical-stage vaccine company developing immunotherapies and infectious-disease vaccines using enveloped virus-like particle and protein-subunit platforms. Comparable as a small-cap clinical-stage vaccine peer pursuing indications with limited current standard of care.

TypeBroad incumbent
Description

Dominant commercial-stage CF therapeutics company. Comparable because Sequoia's third program targets bacterial lung infections in CF patients — same patient population and treatment setting, though Vertex's portfolio is much broader and later stage.

9OM Pharma
TypeDirect peer
Description

Swiss specialty pharma that markets Uro-Vaxom, an immune-stimulating bacterial therapy indicated for prevention of recurrent UTIs. Directly comparable as the only commercial-stage product addressing the same rUTI prevention indication Sequoia's SEQ-400 targets.

TypeBroad incumbent
Description

Major vaccine and pharmaceutical company with a broad infectious-disease vaccine franchise and growing oncology pipeline. Comparable in scope of vaccine and oncology operations relevant to Sequoia's multi-platform strategy.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sequoia Vaccines, Inc

Clinical-Stage Vaccine & Small-Molecule Therapeuticssequoiasciences.com

Sequoia Vaccines, Inc. is a privately held, clinical-stage pharmaceutical company developing a three-program pipeline (SEQ-400 FimH vaccine for recurrent UTIs, SEQ-1274 small molecules for ovarian/uterine cancer, and a CF lung-infection small-molecule platform) for patients affected by antimicrobial-resistant infections and gynecologic cancers.

What Sequoia Vaccines, Inc does

Sequoia Vaccines, Inc. is a privately held, clinical-stage pharmaceutical company advancing a three-program pipeline of vaccine and small-molecule therapeutics. The portfolio is anchored by SEQ-400, a FimH-based vaccine designed to prevent recurrent urinary tract infections as a non-antibiotic alternative, an area situated at the intersection of unmet medical need and the public-health priority around antimicrobial resistance. A second program, SEQ-1274, is a small-molecule platform targeting ovarian and uterine cancer, while a third undisclosed-structure small-molecule platform is directed at cystic fibrosis lung infections. The technology base spans FimH adhesin-based vaccinology and proprietary small-molecule chemistry across infectious disease and oncology indications.

The pipeline addresses three distinct patient populations: women with recurrent UTIs, patients with gynecologic malignancies, and individuals with cystic fibrosis experiencing chronic pulmonary infections. Each program targets a therapeutic area where existing standard of care is either antibiotic-dependent (contributing to AMR), sub-optimal in efficacy, or both. The disclosed leadership group has more than 100 years of combined experience and is supported by a scientific advisory board, although specific credentials are not enumerated in the available data.

As a clinical-stage entity with no disclosed approvals, partnerships, or commercial sales, Sequoia Vaccines' business model is pre-commercial. Value creation is expected to derive from advancing assets through clinical milestones, securing regulatory designations (e.g., FDA priority review, breakthrough, or orphan pathways, particularly under AMR-focused STEDI principles), and eventually out-licensing, partnering, or directly commercializing approved products. No pricing, manufacturing, or go-to-market mechanics are disclosed at this stage.

Sequoia Vaccines, Inc firmographics

Firmographics
Name
Sequoia Vaccines, Inc
Legal name
Sequoia Vaccines, Inc.
Website
https://sequoiasciences.com
Company type
Private
Founded year
2012
Operating status
Operating
Short description
Sequoia Vaccines, Inc. is a privately held, clinical-stage pharmaceutical company developing a three-program pipeline (SEQ-400 FimH vaccine for recurrent UTIs, SEQ-1274 small molecules for ovarian/uterine cancer, and a CF lung-infection small-molecule platform) for patients affected by antimicrobial-resistant infections and gynecologic cancers.
Ownership category
akta.pro rank

Sequoia Vaccines, Inc industry classification

Industry
Product category
Clinical-Stage Vaccine & Small-Molecule Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Vaccine development
  • Antimicrobial resistance
  • Oncology therapeutics
  • Small-molecule drug platform
  • Recurrent UTI prevention

Where Sequoia Vaccines, Inc is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Markets served

Sequoia Vaccines, Inc business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Sequoia Vaccines, Inc product offering

Product offering

Core offering

Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company developing a three-program pipeline: SEQ-400, a FimH-based vaccine for the prevention of recurrent urinary tract infections; the SEQ-1274 small-molecule drug platform for the treatment of ovarian, uterine, and other cancers; and a novel small-molecule drug platform for treating lung infections associated with cystic fibrosis. The portfolio combines vaccine and small-molecule approaches targeting antimicrobial resistance and gynecological cancers.

Product overview

Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company with a three-program product pipeline. The portfolio includes SEQ-400, a FimH vaccine for preventing recurrent UTIs; the SEQ-1274 small-molecule platform targeting ovarian and uterine cancers; and a novel small-molecule drug platform for treating lung infections in cystic fibrosis patients. These programs collectively address antimicrobial resistance and cancer.

Differentiator

Problem solved

Functional benefit

Products and services

  • SEQ-400 SEQ-400 is a FimH vaccine candidate under clinical-stage development for the prevention of recurrent urinary tract infections. FimH is a bacterial adhesin protein found on the surface of uropathogenic E. coli, and the vaccine is intended to interrupt bacterial adhesion, reducing rUTI recurrence and antibiotic dependency.
  • SEQ-1274 Drug Platform SEQ-1274 is a small-molecule oncology drug platform generating candidates for the treatment of ovarian, uterine, and other cancers. The platform is designed to deliver small-molecule therapeutics intended for gynecological and broader oncology indications.
  • Novel Small Molecule Drug Platform for Cystic Fibrosis A drug platform composed of novel small-molecule lead compounds being optimized for the treatment of bacterial lung infections in cystic fibrosis patients, targeting chronic and biofilm-associated infections in the CF lung.

Companies that use Sequoia Vaccines, Inc

Customer profile

Segments3 records

Ideal customer profiles3 records

Sequoia Vaccines, Inc technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sequoia Vaccines, Inc partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Sequoia Vaccines, Inc competitors and assessment

Company assessment

Broad incumbents

  • BioNTech: Global vaccine and immuno-oncology company with mRNA and protein-based vaccine platforms addressing infectious disease and oncology. Comparable in modality (vaccines) and oncology adjacency to Sequoia's small-molecule and vaccine programs.
  • Pfizer: Global pharmaceutical incumbent with both vaccine and oncology franchises (Prevnar, oncology portfolio). Comparable as a benchmark for vaccine manufacturing, regulatory navigation, and oncology small-molecule development that Sequoia would need to compete against or partner with.
  • Moderna: Established vaccine biotech with a broad mRNA and protein-subunit vaccine pipeline, including infectious disease programs. Comparable as a large-scale vaccine platform operator; Sequoia is a much smaller, narrowly focused peer in the vaccine technology space.
  • Vertex Pharmaceuticals: Dominant commercial-stage CF therapeutics company. Comparable because Sequoia's third program targets bacterial lung infections in CF patients — same patient population and treatment setting, though Vertex's portfolio is much broader and later stage.
  • GlaxoSmithKline: Major vaccine and pharmaceutical company with a broad infectious-disease vaccine franchise and growing oncology pipeline. Comparable in scope of vaccine and oncology operations relevant to Sequoia's multi-platform strategy.

Emerging players

  • Innovation Pharmaceuticals: Clinical-stage biopharmaceutical company developing novel small-molecule and biologic therapies, including anti-infectives. Comparable as a small clinical-stage peer with multi-program pipeline across infectious disease and oncology.
  • Aprea Therapeutics: Clinical-stage small-molecule oncology company developing targeted therapies for cancer indications with high unmet need. Comparable in being a small private/clinical-stage biotech with a small-molecule platform addressing oncology indications similar to Sequoia's SEQ-1274 program.
  • Novavax: Clinical-to-commercial vaccine biotech using protein-subunit and nanoparticle vaccine platforms. Comparable to Sequoia in relying on recombinant protein-subunit vaccine technology, though at a much later development stage and broader indication scope.
  • VBI Vaccines: Clinical-stage vaccine company developing immunotherapies and infectious-disease vaccines using enveloped virus-like particle and protein-subunit platforms. Comparable as a small-cap clinical-stage vaccine peer pursuing indications with limited current standard of care.

Direct peers

  • OM Pharma: Swiss specialty pharma that markets Uro-Vaxom, an immune-stimulating bacterial therapy indicated for prevention of recurrent UTIs. Directly comparable as the only commercial-stage product addressing the same rUTI prevention indication Sequoia's SEQ-400 targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Sequoia Vaccines, Inc social profiles

Digital presence

Sequoia Vaccines, Inc financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sequoia Vaccines, Inc leadership team

Management profile

Number of profiles

Sequoia Vaccines, Inc funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sequoia Vaccines, Inc M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sequoia Vaccines, Inc

What does Sequoia Vaccines, Inc do?

Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company developing a three-program pipeline: SEQ-400, a FimH-based vaccine for the prevention of recurrent urinary tract infections; the SEQ-1274 small-molecule drug platform for the treatment of ovarian, uterine, and other cancers; and a novel small-molecule drug platform for treating lung infections associated with cystic fibrosis. The portfolio combines vaccine and small-molecule approaches targeting antimicrobial resistance and gynecological cancers.

Is Sequoia Vaccines, Inc a public or private company?

Sequoia Vaccines, Inc is a private company. It is classified as unknown and is currently operating.

When was Sequoia Vaccines, Inc founded?

Sequoia Vaccines, Inc was founded in 2012.

Where is Sequoia Vaccines, Inc based?

Sequoia Vaccines, Inc is headquartered in St Louis, United States, in the North America region.

Who are Sequoia Vaccines, Inc's main competitors?

Broad incumbents on record are BioNTech, Pfizer, Moderna, Vertex Pharmaceuticals and GlaxoSmithKline. Emerging players are Innovation Pharmaceuticals, Aprea Therapeutics, Novavax and VBI Vaccines. OM Pharma is listed as a direct peer.

Does Sequoia Vaccines, Inc have an API?

No public API is recorded for Sequoia Vaccines, Inc.

What industry is Sequoia Vaccines, Inc in?

Sequoia Vaccines, Inc's product category is Clinical-Stage Vaccine & Small-Molecule Therapeutics. Its primary akta.pro industry code is HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection), with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals